MindMed

Today, we reported our Q4 and full year 2024 financial results and business updates. The company hosted a conference call this morning, available for replay. Learn more here: https://bit.ly/4i2HV00

Our CEO, Robert Barrow will participate in a fireside chat at the Leerink Partners Global Healthcare 2025 Conference on Tuesday, March 11th, at 3:40pm EDT. Find details here: https://bit.ly/43F0TFV

Our CMO, Dan Karlin, discussed with Psychiatric Times our MM120 ODT Phase 3 program in patients with #GAD and what this means for the future of psychiatry. Check out the full interview here: https://bit.ly/4jcBZCH

#EmployeeSpotlight ?? Meet Michelle M., our dedicated Clinical Trial Manager at MindMed. Starting her career in academia, Michelle transitioned to biotech driven by her passion for helping people with brain health disorders. Her journey reflects our mission to bring innovative mental health treatments to those in need. #InsideMindMed

#ICYMI We recently announced the dosing of the first patients in our Voyage and Panorama Phase 3 studies evaluating MM120 ODT for #GeneralizedAnxietyDisorder. To the patients participating in this study, thank you for your courage and trust in our clinical study. Your participation is critical to advancing a novel treatment and bringing hope to others with GAD. We also extend our gratitude to the investigators and study coordinators for their continued support. Data from the 12-week double-blind from both studies is expected in 2026. Learn more: https://bit.ly/42QGCfN

?At MindMed, we are committed to transforming the treatment landscape for brain health disorders through evidence-based innovative solutions. Learn more about our programs and research: https://bit.ly/40MooJW

Our Chief Executive Officer, Robert Barrow shares insights with Biotech TV on the need for new approaches to address anxiety and depression and the growing interest in psychedelic medicines as we advance our phase 3 studies: Watch full interview here: https://bit.ly/3EyuTZj #BrainHealthDisorders

We’re looking forward to presenting at the Oppenheimer & Co. Inc. 35th Annual Healthcare Life Sciences Conference. Find more information here: https://bit.ly/42IRo88

Today, we announced that the first patient has been dosed in Panorama, our second pivotal Phase 3 study of MM120 ODT for the treatment of #GeneralizedAnxietyDisorder. This is the second Phase 3 trial of LSD as an oral treatment aimed at addressing this condition. We extend our gratitude to our investigators, clinical trial sites, and patients in the United States and Europe who will participate in this pioneering research. Topline data from the study is anticipated in 2H 2026. To learn more about the Panorama study, read our full press release https://bwnews.pr/4gkjF85.

As 2024 winds down, we reflect and celebrate our milestones! Thank you to our hard-working, dedicated team and partners for making these accomplishments possible. Here’s to building on this momentum and making 2025 even more productive.